PBAC's latest decision on Morphine sulfate pentahydrate: Recommended with restriction (2024). Considered for Treatment of severe pain, cancer pain, and severe disabling pain. The drug is for short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2019
Submissions
2
2019 → 2024
Eligible population
Adults requiring treatment of severe pain, cancer pain, or severe disabling pain, who have had inadequate pain management with maximum tolerated doses of non-opioid and other opioid analgesics, or are unable to use these due to contraindications or intolerance.
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
Not modelled. This is a relisting of a previously delisted product (delisted August 2023) with no new economic evaluation required.
Submission history
Mar 2019: Recommended with restriction · Restricted
Jul 2024: Recommended with restriction · Restricted